RT Journal Article
T1 Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.
A1 Martinón-Torres, Federico
A1 Halperin, Scott A
A1 Nolan, Terry
A1 Tapiéro, Bruce
A1 Perrett, Kirsten P
A1 de la Cueva, Ignacio Salamanca
A1 García-Sicilia, José
A1 Stranak, Zbynek
A1 Vanderkooi, Otto G
A1 Kosina, Pavel
A1 Rumlarova, Sarka
A1 Virta, Miia
A1 Arribas, Jose M Merino
A1 Miranda-Valdivieso, Mariano
A1 Novas, Begoña Arias
A1 Bozensky, Jan
A1 Ortega, María José Cilleruelo
A1 Amador, Jose Tomas Ramos
A1 Baca, Manuel
A1 Palomino, Esperanza Escribano
A1 Zuccotti, Gian Vincenzo
A1 Janota, Jan
A1 Marchisio, Paola Giovanna
A1 Kostanyan, Lusine
A1 Meyer, Nadia
A1 Ceregido, Maria Angeles
A1 Cheuvart, Brigitte
A1 Kuriyakose, Sherine O
A1 Mesaros, Narcisa
K1 Blunting
K1 Booster
K1 Maternal immunization
K1 Pertussis
K1 Tdap vaccine
K1 Toddlers
AB Transplacentally transferred antibodies induced by maternal pertussis vaccination interfere with infant immune responses to pertussis primary vaccination. We evaluated whether this interference remains in toddlers after booster vaccination. In a prior phase IV, observer-blind, placebo-controlled, randomized study (NCT02377349), pregnant women in Australia, Canada and Europe received intramuscular tetanus-reduced-antigen-content diphtheria-three-component acellular pertussis vaccine (Tdap group) or placebo (control group) at 270/7-366/7 weeks' gestation, with crossover immunization postpartum. Their infants were primed (study NCT02422264) and boosted (at 11-18 months; current study NCT02853929) with diphtheria-tetanus-three-component acellular pertussis-hepatitis B virus-inactivated poliovirus/Haemophilus influenzae type b vaccine (DTaP-HepB-IPV/Hib) and 13-valent pneumococcal conjugate vaccine. Immunogenicity before and after booster vaccination, and reactogenicity and safety of the booster were evaluated descriptively. 263 (Tdap group) and 277 (control group) toddlers received a DTaP-HepB-IPV/Hib booster. Pre-booster vaccination, observed geometric mean concentrations (GMCs) for the three pertussis antigens and diphtheria were 1.4-1.5-fold higher in controls than in the Tdap group. No differences were observed for the other DTaP-HepB-IPV/Hib antigens. One month post-booster vaccination, booster response rates for pertussis antigens were ≥ 92.1% and seroprotection rates for the other DTaP-HepB-IPV/Hib antigens were ≥ 99.2% in both groups (primary objective). Higher post-booster GMCs were observed in controls versus the Tdap group for anti-filamentous hemagglutinin (1.2-fold), anti-pertussis toxoid (1.5-fold) and anti-diphtheria (1.4-fold). GMCs for the other DTaP-HepB-IPV/Hib antigens were similar between groups. Serious adverse events were reported for three toddlers (controls, not vaccination-related). One death occurred pre-booster (Tdap group, not vaccination-related). As a consequence of interference of maternal pertussis antibodies with infant immune responses to pertussis primary vaccination, pertussis antibody concentrations were still lower in toddlers from Tdap-vaccinated mothers before DTaP-HepB-IPV/Hib booster vaccination. After the booster, antibody concentrations were lower for filamentous hemagglutinin and pertussis toxoid but not for pertactin. The clinical significance of this interference requires further evaluation. ClinicalTrials.gov: NCT02853929.
YR 2021
FD 2021-02-19
LK http://hdl.handle.net/10668/17210
UL http://hdl.handle.net/10668/17210
LA en
DS RISalud
RD Apr 6, 2025